Letermovir Patent Expiration

Letermovir was first introduced by Merck Sharp And Dohme Corp in its drug Prevymis on Nov 8, 2017. 2 different companies have introduced drugs containing Letermovir.


Letermovir Patents

Given below is the list of patents protecting Letermovir, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Prevymis US10603384 Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative Feb 28, 2033 Merck Sharp Dohme
Prevymis USRE46791 Substituted dihydroquinazolines Jan 18, 2029 Merck Sharp Dohme
Prevymis US7196086 Substituted dihydroquinazolines May 22, 2024

(Expired)

Merck Sharp Dohme
Prevymis US8513255 Substituted dihydroquinazolines May 22, 2024

(Expired)

Merck Sharp Dohme



Letermovir's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List